Latest positive preclinical data provides another step in the path to potential IND submission this year for novel ketamine analog MIAMI, FL / ACCESSWIRE / July 25, 2024 / MIRA Pharmaceuticals, Inc.
BUFFALO, N.Y. – Drugs that act on NMDA (N-methyl-D-aspartate) receptors, which are essential for learning, memory and moment-by-moment consciousness, are key for treating neuropsychiatric disorders.
(a) Diagram illustrating the ion channel activity in post-synaptic neurons. AMPA receptors are involved in the activation of post-synaptic neurons, while NMDA receptors are blocked by magnesium ions ...
LA JOLLA, Calif.--(BUSINESS WIRE)--Arialys Therapeutics, a clinical-stage biotechnology company pioneering new precision medicines for autoimmune neuropsychiatric diseases, today announced the ...
A new study suggests a potential molecular strategy for treating fragile X syndrome, an inherited neurodevelopmental disorder that causes autism spectrum disorder and intellectual disability. This ...
Immune checkpoint inhibitors have reshaped cancer treatment over the past decade, but the same immune activation that shrinks tumors can also turn against healthy tissue, including the brain. A ...
Scientists Identified Alzheimer’s Hidden “Death Switch” and Found a Way to Shut It Down ...